Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus famitinib vs chemotherapy in recurrent/metastatic cervical cancer
NCT04906993Phase 3Active, not recruiting
- Sponsor
- Hengrui
- Start
- Jul 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, famitinib in Cervical Cancer (CC), sponsored by Hengrui. Started Jul 2021; status: active, not recruiting.
02
Drugs
camrelizumabfamitinib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04906993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906993.